The U.S. government voucher program designed to encourage drug development for rare childhood diseases is set to expire at the end of this month. This program, established in 2012, provides vouchers to groups who successfully get a drug in the rare disease area approved. The vouchers act as a fastpass at Disneyland, allowing the holder to request the FDA review a drug within six months rather than the usual 10. However, the program has faced criticism over the years for being ineffective, convoluted, and seen as a handout to pharmaceutical companies, as the vouchers can be sold. Despite the criticism, for some researchers, this program is the only way to fund their work.
Terry Pirovolakis, whose son was diagnosed with a rare disease five years ago, expressed concern about the potential impact of the program’s expiration. He stated, “Unfortunately, if the voucher goes away, it’ll be a significant hit to rare disease research.” The future of this program remains uncertain as the deadline approaches.
In other news, the FDA has announced an investigation into toxic metals found in tampons. A recent study discovered toxic metals like arsenic and lead in commercially available tampons, raising concerns about potential health risks. The FDA has commissioned an independent literature review to evaluate the existing data on chemicals in tampons and any associated health effects. While the study has sparked worries among consumers, experts caution that the research does not provide conclusive evidence of harm, as there is limited research on the absorption of these metals.
Additionally, the FDA has issued a letter to pharmaceutical company AbbVie, criticizing a TV ad featuring Serena Williams for making false and misleading claims about their migraine pill. The agency raised concerns about the use of a celebrity athlete in the ad, stating that it amplifies the misleading suggestions about the drug due to Williams’ credibility.
A study published in the American Journal of Psychiatry has revealed that high doses of amphetamines, such as Adderall, are associated with a higher risk of psychosis. Researchers found that individuals who took high doses of amphetamines were five times more likely to develop psychosis or mania compared to those who did not take these medications. The findings emphasize the importance of caution when prescribing high doses of amphetamines.
Furthermore, a surprising discovery was made in Texas wastewater samples, where H5N1 bird flu viruses were detected in all 10 cities where samples were collected. The widespread detection of the virus in wastewater has raised concerns about potential animal sources of the virus and its implications for public health.
On a brighter note, three women have been awarded the Blavatnik National Awards for Young Scientists, marking the second time in the award’s history that women have won in all three categories. The winners, Cigall Kadoch, Markita del Carpio Landry, and Britney E. Schmidt, received a cash prize of $250,000 each for their contributions to the fields of life sciences, chemical sciences, and physical sciences and engineering, respectively.
As the healthcare landscape continues to evolve, it is crucial to stay informed about the latest developments and research findings to ensure the health and well-being of individuals.
